ESC Professional Premium Access

Effect of low-dose rivaroxaban with low-dose aspirin vs low-dose aspirin on platelet and oxidative biomarkers: a randomized study in diabetes patients with stable peripheral or coronary artery disease

Congress Presentation

About the speaker

Associate Professor Bianca Rocca

Catholic University School of Medicine, Rome (Italy)
7 presentations
0 follower

6 more presentations in this session

A randomized, cross-over study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of milvexian with single and dual antiplatelet therapy in healthy participants

Speaker: Doctor G. Abelian (US)

Thumbnail

Antithrombotic strategies in antiphospholipid syndrome with arterial thrombosis: a systematic review and network meta-analysis

Speaker: Doctor T. Attachaipanich (Chiang Mai, TH)

Thumbnail

Combined anticoagulant and antiplatelet therapy is associated with an improved outcome in hospitalised patients with COVID-19: a propensity matched cohort study

Speaker: Doctor K. Matli (Beirut, LB)

Thumbnail

CS014 is a novel HDAC inhibitor regulating the platelet activity, fibrinolysis and clot stability for prevention of thrombosis without increased risk of bleeding

Speaker: Associate Professor M. Holinstat (Ann Arbor, US)

Thumbnail

Aspirin therapy on prophylactic anticoagulation for hospitalized patients with COVID-19: A propensity score-matched cohort analysis of the HOPE-COVID-19 registry.

Speaker: Doctor F. Santoro (Foggia, IT)

Thumbnail

Access the full session

Challenges and advances in antithrombotic therapy

Speakers: Associate Professor B. Rocca, Doctor G. Abelian, Doctor T. Attachaipanich, Doctor K. Matli, Associate Professor M. Holinstat...
Thumbnail

About the event

Image

ESC Congress 2022

26 August - 29 August 2022

Sessions Presentations

ESC 365 is supported by

logo Novo Nordisk